Login to Your Account

Trubion, Facet Joining Forces on Early-Stage Leukemia Drug

By Catherine Hollingsworth

Monday, August 31, 2009
Trubion Pharmaceuticals Inc. has entered collaboration with Facet Biotech Corp. to jointly develop Phase I TRU-016 for chronic lymphocytic leukemia, in a deal worth up to $206.5 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription